SARS-CoV-2 vaccination: Long-Term Follow-up of Pre-Existing and De Novo Immune Thrombocytopenia (ITP).
Marina Beltrami-MoreiraJames B BusselEun-Ju LeePublished in: Thrombosis and haemostasis (2022)
In this single-center retrospective study, 17% (16/95) of patients with pre-existing ITP experienced an ITP exacerbation after SARS-CoV-2 vaccination(s): 10/84 post-dose#1, 9/73 post-dose#2, and 5/24 post-booster. Several of these patients tolerated previous vaccinations or received subsequent doses without ITP exacerbation. Among 11 patients who received rescue treatment, 7 had pre-existing, difficult-to-control ITP; exacerbations in these 7 may not have been caused by the vaccine. Six separate patients with de novo ITP post-SARS-CoV-2 vaccine who were followed for a median of 11 months (range 3-15) responded well to standard treatments for ITP and had favorable longer-term outcomes.
Keyphrases
- sars cov
- chronic obstructive pulmonary disease
- respiratory syndrome coronavirus
- end stage renal disease
- ejection fraction
- newly diagnosed
- cystic fibrosis
- preterm infants
- type diabetes
- peritoneal dialysis
- metabolic syndrome
- adipose tissue
- prognostic factors
- insulin resistance
- acute respiratory distress syndrome
- combination therapy
- glycemic control
- mechanical ventilation